ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $117,090 | +2.3% | 5,837 | +43.9% | 0.01% | +25.0% |
| Q2 2023 | $114,448 | +80.8% | 4,057 | +10.2% | 0.00% | +33.3% |
| Q1 2023 | $63,313 | -25.2% | 3,681 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $84,626 | +7.1% | 3,681 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $79,000 | +2.6% | 3,681 | +33.8% | 0.00% | +33.3% |
| Q2 2022 | $77,000 | -39.4% | 2,752 | 0.0% | 0.00% | -40.0% |
| Q1 2022 | $127,000 | -45.0% | 2,752 | 0.0% | 0.01% | -37.5% |
| Q4 2021 | $231,000 | +26.2% | 2,752 | 0.0% | 0.01% | +14.3% |
| Q3 2021 | $183,000 | +31.7% | 2,752 | +5.6% | 0.01% | +40.0% |
| Q2 2021 | $139,000 | +33.7% | 2,607 | +8.3% | 0.01% | +25.0% |
| Q1 2021 | $104,000 | -16.8% | 2,408 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $125,000 | +316.7% | 2,408 | +163.7% | 0.01% | +500.0% |
| Q3 2020 | $30,000 | -31.8% | 913 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $44,000 | – | 913 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |